Аpproaches to the production of theranostic couples of radiopharmaceuticals for the diagnosis and treatment of prostate cancer: a literature review

Abstract

Currently, prostate cancer (PC) is one of the most common malignant neoplasms in men. More than 400,000 cases of prostate cancer are diagnosed annually in the world; in a number of countries, it occupies the second or third place in the structure of oncological diseases. A promising technology for the diagnosis and treatment of oncological diseases in nuclear medicine is radiotheranostics as an integrated approach that combines diagnostics and therapy using a single chemical molecule, but different ratioisotopes. For prostate cancer, the diagnostic radioisotope 68Ga and the therapeutic isotopes — 177Lu and 225Ac are used. The article discusses modern technologies for the production of radiopharmaceuticals for the diagnosis and radionuclide treatment of prostate cancer using theranostic pairs based on 68Ga/177Lu isotopes, as well as the prospects for the synthesis of new therapeutic radiopharmaceuticals labeled with the 177Lu isotope.